肝癌类器官模型在精准药物筛选中的创新应用

doi:10.3969/j.issn.1004-616x.2026.02.013

摘要/Abstract

摘要： 肝癌是导致癌症相关死亡的主要原因之一，其高发病率和高死亡率使有效治疗药物的研发尤为迫切。尽管现有的治疗手段如手术、化疗和靶向治疗在一定程度上延长了患者的生存期，但肝癌的治疗仍面临诸多挑战，其中包括药物耐受性等。因此，探索更加精准的药物筛选模型进行新药筛选成为肝癌研究的重要方向。本文系统综述了肝癌类器官模型在精准药物筛选中的创新应用，分析了肝癌的病理现状及治疗方法，指出现有治疗手段的不足及新药研发的必要性。重点介绍了类器官技术的起源、发展及其在肝癌研究中的应用，特别是其在药物筛选中的独特优势。通过实例分析，展示了肝癌类器官在新药发现中的实际应用，并探讨了共培养系统、生物打印技术、微流控技术以及人工智能在类器官技术中的最新进展。

关键词: 肝癌, 类器官, 药物筛选, 肝癌治疗

中图分类号:

R735.7

吉方圆, 苏源莹, 余昊霖, 郭飞, 谢剑君, 彭江云. 肝癌类器官模型在精准药物筛选中的创新应用[J]. 癌变·畸变·突变, 2026, 38(2): 166-172.

参考文献

[1] HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
[2] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3):209-249.
[3] DONNE R, LUJAMBIO A. The liver cancer immune microenvironment:Therapeutic implications for hepatocellular carcinoma[J]. Hepatology,2023, 77(5):1773-1796.
[4] YANG S Q, HU H J, KUNG H, et al. Organoids:The current status and biomedical applications[J]. MedComm, 2023, 4(3):e274.
[5] WILSON H V. A new method by which sponges may be artificially reared[J]. Science, 1907, 25(649):912-915.
[6] THOMSON J A, ITSKOVITZ-ELDOR J, SHAPIRO S S, et al.Embryonic stem cell lines derived from human blastocysts[J]. Science,1998, 282(5391):1145-1147.
[7] EIRAKU M, WATANABE K, MATSUO-TAKASAKI M, et al.Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals[J]. Cell Stem Cell, 2008, 3(5):519-532.
[8] SATO T, VRIES R G, SNIPPERT H J, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J].Nature, 2009, 459(7244):262-265.
[9] XU R, ZHOU X T, WANG S K, et al. Tumor organoid models in precision medicine and investigating cancer-stromal interactions[J].Pharmacol Ther, 2021, 218:107668.
[10] DI LULLO E, KRIEGSTEIN A R. The use of brain organoids to investigate neural development and disease[J]. Nat Rev Neurosci, 2017,18(10):573-584.
[11] CORRÒC, NOVELLASDEMUNT L, LI V S W. A brief history of organoids[J]. Am J Physiol Cell Physiol, 2020, 319(1):C151-C165.
[12] HAN X X, CAI C H, DENG W, et al. Landscape of human organoids:Ideal model in clinics and research[J]. Innovation, 2024, 5(3):100620.
[13] U.S. Food and Drug Administration. FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs[EB/OL].(2025-04-10)https://www.fda.gov/news-events/press-announcements/fda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs.
[14] HUCH M, BOJ S F, CLEVERS H. Lgr5(+)liver stem cells, hepatic organoids and regenerative medicine[J]. Regen Med, 2013, 8(4):385-387.
[15] SKARDAL A, DEVARASETTY M, RODMAN C, et al. Liver-tumor hybrid organoids for modeling tumor growth and drug response in vitro[J]. Ann Biomed Eng, 2015, 43(10):2361-2373.
[16] BROUTIER L, MASTROGIOVANNI G, VERSTEGEN M M, et al.Human primary liver cancer-derived organoid cultures for disease modeling and drug screening[J]. Nat Med, 2017, 23(12):1424-1435.
[17] NUCIFORO S, FOFANA I, MATTER M S, et al. Organoid models of human liver cancers derived from tumor needle biopsies[J]. Cell Rep,2018, 24(5):1363-1376.
[18] NARAYAN N J C, REQUENA D, LALAZAR G, et al. Human liver organoids for disease modeling of fibrolamellar carcinoma[J]. Stem Cell Reports, 2022, 17(8):1874-1888.
[19] LIU J Y, LI P F, WANG L, et al. Cancer-associated fibroblasts provide a stromal niche for liver cancer organoids that confers trophic effects and therapy resistance[J]. Cell Mol Gastroenterol Hepatol, 2021, 11(2):407-431.
[20] DING Z W, PAN Y F, SHANG T Y, et al. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers[J]. Nat Commun, 2023, 14(1):6269.
[21] CAO W L, LIU J Y, WANG L, et al. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors[J]. Carcinogenesis, 2019, 40(1):145-154.
[22] ARTEGIANI B, VAN VOORTHUIJSEN L, LINDEBOOM R G H, et al.Probing the tumor suppressor function of BAP1 in CRISPR-engineered human liver organoids[J]. Cell Stem Cell, 2019, 24(6):927-943.e6.
[23] NICOSIA L, PRANKE I, LATORRE R V, et al. Adenine base editing with engineered virus-like particles rescues the CFTR mutation G542X in patient-derived intestinal organoids[J]. iScience, 2025, 28(3):111979.
[24] GIRON-MICHEL J, PADELLI M, OBERLIN E, et al. State-of-the-art liver cancer organoids:modeling cancer stem cell heterogeneity for personalized treatment[J]. BioDrugs, 2025, 39(2):237-260.
[25] LI L, KNUTSDOTTIR H, HUI K, et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity[J]. JCI Insight, 2019, 4(2):e121490.
[26] JI S Y, FENG L, FU Z L, et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology[J]. Sci Transl Med, 2023, 15(706):eadg3358.
[27] YANG H, CHENG J H, ZHUANG H, et al. Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer[J]. Cancer Cell, 2024, 42(4):535-551.e8.
[28] BLUKACZ L, NUCIFORO S, FUCILE G, et al. Inhibition of the transmembrane transporter ABCB1 overcomes resistance to doxorubicin in patient-derived organoid models of HCC[J]. Hepatol Commun, 2024,8(5):e0437.
[29] WANG S Q, WANG Y, XUN X D, et al. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids[J]. J Exp Clin Cancer Res, 2020, 39(1):22.
[30] XIAN L F, ZHAO P, CHEN X, et al. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer[J]. Cell Oncol, 2022, 45(5):1019-1036.
[31] HUANG X B, FANG R Y, PANG Y Q, et al. HHLA2 activates c-Met and identifies patients for targeted therapy in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2025, 44(1):153.
[32] TANG P J, HAN Z W, ZHAO Y M, et al. ALG3 as a prognostic biomarker and mediator of PD-1 blockade resistance in hepatocellular carcinoma[J]. Front Immunol, 2025, 16:1589153.
[33] WANG W W, YUAN T G, MA L L, et al. Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors[J].Adv Sci, 2022, 9(22):2105810.
[34] ZHU Y J, TANG S J, YUAN Q Y, et al. Integrated characterization of hepatobiliary tumor organoids provides a potential landscape of pharmacogenomic interactions[J]. Cell Rep Med, 2024, 5(2):101375.
[35] SUN L, WAN A H, YAN S J, et al. A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance[J]. Acta Pharm Sin B, 2024, 14(1):223-240.
[36] LI L, HALPERT G, LERNER M G, et al. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma[J]. JCI Insight, 2021, 6(12):e138197.
[37] LIM J T C, KWANG L G, HO N C W, et al. Hepatocellular carcinoma organoid co-cultures mimic angiocrine crosstalk to generate inflammatory tumor microenvironment[J]. Biomaterials, 2022, 284:121527.
[38] ZHAO Y Y, LI Y X, ZHANG W J, et al. 3D-bioprinted liver cancer models derived from primary hepatocytes for simulating cancer initiation and drug screening[J]. Hepatol Commun, 2025, 9(11):e0823.
[39] ZOU Z Y, LIN Z, WU C L, et al. Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients[J]. Adv Sci, 2023, 10(27):2302640.
[40] TAN S Y, DING Y, WANG W, et al. Development of an AI model for DILI-level prediction using liver organoid brightfield images[J].Commun Biol, 2025, 8(1):886.
[41] WEI L, HU G L, XU B, et al. Effects of hydrogel stiffness and viscoelasticity on organoid culture:a comprehensive review[J]. Mol Med,2025, 31(1):83.
[42] WANG Y, TAKEISHI K, LI Z, et al. Microenvironment of a tumor-organoid system enhances hepatocellular carcinoma malignancyrelated hallmarks[J]. Organogenesis, 2017, 13(3):83-94.